17 December
2024
AOTI, INC. (the "Company" or
"Group" or "AOTI")
Grant of performance share
awards to CFO under Long Term Incentive Plan
AOTI, INC., a medical technology
group focused on the durable healing of wounds and prevention of
amputations, announces that on 17th December 2024, the Company
granted awards over ordinary shares in the form of nominal cost
options (Performance Awards) under the AOTI Long Term Incentive
Plan (LTIP) to Jayesh Pankhania, CFO, who joined AOTI in June 2024
and is a Person Discharging Managerial Responsibilities (PDMR), as
detailed below:
|
PDMR
|
Role
|
Number of Performance Awards
|
Exercise Price ($)
|
|
Jayesh Pankhania
|
Chief Financial Officer
|
208,333
|
0.00001
|
In determining the number of awards,
the Company has used a share price of 132p, being the IPO
price.
The Performance Awards will vest
three years from the grant date conditional on meeting three-year
performance conditions as described below.
40% of an award is subject to a
revenue growth performance condition measured over a three-year
period ending 31 December 2026.
30% of an award is subject to a
relative total shareholder return (TSR) performance condition
measured over three years from the date of the IPO. AOTI's TSR
performance will be measured against a sector peer group of UK, US
and other internationally quoted companies with 25% of this portion
of the award vesting at median performance rising on a straight
line to full vesting at upper quartile performance.
30% of an award is subject to an
absolute total shareholder return performance condition measured
over three years from the date of the IPO. Vesting will commence
from zero at 10% compound annual growth rising on a straight line
to full vesting at 20% compound annual growth.
END
|
AOTI, INC.
Dr. Mike Griffiths, Chief Executive
Officer
Jayesh Pankhania, Chief Financial
Officer
|
+44 (0)20 3727 1000
ir@aotinc.net
|
|
Peel Hunt LLP (Nominated Adviser and Broker)
Dr. Christopher Golden, Patrick
Birkholm
|
+44 (0)20 7418 8900
|
|
FTI
Consulting (Financial PR & IR)
Ben Atwell, Simon Conway,
Natalie Garland-Collins, Alex
Davis
|
+44 (0)20 3727 1000
AOTI@fitconsulting.com
|
ABOUT AOTI, INC.
AOTI, INC. was founded in 2006 and
is based in Oceanside, California, US and Galway, Ireland,
providing innovative solutions to resolve severe and chronic wounds
worldwide. Its products reduce healthcare costs and improve the
quality of life for patients with these debilitating conditions.
The Company's patented non-invasive Topical Wound Oxygen
(TWO2®) therapy has demonstrated in
differentiating, robust, double-blinded randomised controlled
trials (RCT) and real-world evidence (RWE) studies to more-durably
reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in
an unprecedented 88 per cent reduction in hospitalisations and 71
per cent reduction in amputations over 12 months.
TWO2® therapy can be administered by the
patient at home, improving access to care and enhancing treatment
compliance. TWO2® therapy has received
regulatory clearance from the US (FDA), Europe (CE Mark), UK
(MHRA), Health Canada, the Chinese National Medical Products
Administration, Australia (TGA) and in Saudi Arabia. Also
see www.aotinc.net
|
1.
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Jayesh Pankhania
|
|
2.
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial
notification/Amendment
|
Initial Notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AOTI, INC.
|
|
b)
|
LEI
|
213800ZGCNDSTWIRK687
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument
|
Ordinary Shares
|
|
b)
|
Identification code
|
US03690C1027
|
|
c)
|
Nature of the
transactions
|
Initial award under the AOTI
LTIP
|
|
d)
|
Price(s) and volume(s)
|
Exercise Price: 0p per
share
Volume: 208,333
|
|
e)
|
Aggregated information
- Aggregated volume
- Price
|
As for d) above
|
|
f)
|
Date of the transactions
|
17 December 2024
|
|
f)
|
Place of the transactions
|
Outside a trading venue
|
